| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T41 |
0-362 |
Sentence |
denotes |
To accomplish the task of characterizing site-specific glycosylation of the trimer Spike of SARS-CoV-2 and the host receptor ACE2, we began by expressing and purifying a stabilized, soluble trimer Spike glycoprotein mimetic immunogen (that we define here and forward as S, [Yu et al., 2020]) and a soluble version of the ACE2 glycoprotein from a human cell line. |
| T42 |
363-545 |
Sentence |
denotes |
We utilized multiple mass-spectrometry-based approaches, including glycomic and glycoproteomic approaches, to determine occupancy and site-specific heterogeneity of N-linked glycans. |
| T43 |
546-729 |
Sentence |
denotes |
Occupancy (i.e., the percent of any given residue being modified by a glycan) is an important consideration when developing neutralizing antibodies against a glycan-dependent epitope. |
| T44 |
730-841 |
Sentence |
denotes |
We also identified sites of O-linked glycosylation and the heterogeneity of the O-linked glycans on S and ACE2. |
| T45 |
842-1057 |
Sentence |
denotes |
We leveraged this rich dataset, along with existing 3D-structures of both glycoproteins, to generate static and molecular dynamics (MD) models of S alone, and in complex with the glycosylated, soluble ACE2 receptor. |
| T46 |
1058-1333 |
Sentence |
denotes |
By combining bioinformatics characterization of viral evolution and variants of S and ACE2 with MD simulations of the glycosylated S-ACE2 interaction, we identified important roles for glycans in multiple processes, including receptor-viral binding and glycan shielding of S. |
| T47 |
1334-1572 |
Sentence |
denotes |
Our rich characterization of the recombinant, glycosylated S trimer mimetic immunogen of SARS-CoV-2 in complex with the soluble human ACE2 receptor provides a detailed platform for guiding rational vaccine, antibody, and inhibitor design. |
